The GIFT Trial - Will Genotype-Guided Dosing of Warfarin Catch On? (CE Program)

Print
Moderator: 
Pau Solinsky, PharmD
Panelists: 
Daniel Witt, PharmD, BCPS
Edith Nutescu, PharmD, MS CTS
Reviewed By: 
Stuart T. Haines, PharmD, BCPS, BCACP
Citation: 
Gage BF, Bass AR, Lin H, et al. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. JAMA. 2017;318(12):1115-1124

The Genetics Informatics Trial (GIFT) examined the potential benefits of using genotype information to personalize the dosing of warfarin therapy in patients undergoing elective hip or knee replacement surgery.  Previous trials have not consistently shown that genotype-guided warfarin dosing is beneficial.  Dr. Paul Solinsky reviews the methods and results of the GIFT Trial and our panelists, Dr. Daniel Witt and Dr. Edith Nutescu, discuss the study implications.

 

To earn pharmacy continuing education credit for this program, please visit PharmacyCPD.org.  This FREE CE program is supported by tax-deductible donations from iForumRx members.  Consider giving a donation to the University of Mississippi Foundation to support iForumRx today.